AZN - AstraZeneca Beefs Up Its Endocrine Disease Pipeline With Amolyt Pharma Deal Worth $1.05B | Benzinga
Thursday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases.
Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion on a cash and debt-free basis, including $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
The proposed ...